Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00990184
Recruitment Status : Completed
First Posted : October 6, 2009
Results First Posted : November 21, 2012
Last Update Posted : November 21, 2012
VA Puget Sound Health Care System
Information provided by (Responsible Party):
Seattle Institute for Biomedical and Clinical Research

Brief Summary:
The objective of this study is to determine the effect of 8 weeks of treatment with colesevelam HCl 3.75 g once daily with the evening meal on ß-cell function by evaluating the acute insulin response (AIRg) to an intravenous glucose load in subjects with prediabetes (impaired fasting glucose).

Condition or disease Intervention/treatment Phase
Impaired Fasting Glucose Prediabetes Drug: Colesevelam Other: placebo Phase 3

Detailed Description:

Colesevelam is a bile acid sequestrant that was initially approved for treatment of patients with dyslipidemia. Subsequently it was observed that patients with type 2 diabetes receiving this medication had improved glucose control. However, the mechanism(s) by which it lowers glucose concentrations has not been determined.

Glucose metabolism is enhanced following oral nutrient ingestion by the action of the incretin hormones. The two major incretin hormones are the peptides glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), which are released from the intestinal tract wall in response to a meal. Of these two peptides, GLP-1 appears to be more important in regulating glucose metabolism. In the presence of elevated plasma glucose, GLP-1 promotes insulin release from the ß-cells of the pancreas. GLP-1 also suppresses glucagon release, and thereby inhibits hepatic glucose output. Administration of GLP-1 by infusion or by subcutaneous injection has been shown to improve glucose tolerance in type 2 diabetic patients.

The purpose of this study is therefore to determine in a cohort of individuals with prediabetes, who have an elevated fasting plasma glucose and are at increased risk of developing type 2 diabetes, whether the glucose lowering properties of colesevelam occur by it improving insulin sensitivity, islet ß-cell function or both. Further, by assessing the effect of colesevelam on incretin hormone release, it will be possible to determine whether any improvement in islet ß-cell function is due to enhanced incretin stimulation.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Single-Blind Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)
Study Start Date : September 2009
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy Prediabetes

Arm Intervention/treatment
Experimental: Colesevelam Hydrochloride Drug: Colesevelam
colesevelam HCl 3.75 g once daily orally with the evening meal
Other Name: colesevelam HCl

Other: placebo
tablet (s) orally given with evening meal

Primary Outcome Measures :
  1. Acute Insulin Response (AIRg) to Intravenous Glucose [ Time Frame: Baseline and 8 weeks ]
    Increase in insulin following glucose injection. AIRg is measured as the magnitude of the insulin response to an intravenous glucose injection calculated over the 10 minutes following glucose administration.

Secondary Outcome Measures :
  1. Insulin Sensitivity [ Time Frame: Baseline and 8 weeks ]
    Tissue response to circulating insulin in the blood. Insulin sensitivity is measured using a mathematical model that quantifies the fractional rate of change in glucose concentrations per unit of insulin. Low values are insulin resistant and high values are insulin sensitive. *Please note: the "-1" in the Unit of Measure should be a superscripted value.

  2. Glucose Disappearance Rate [ Time Frame: Baseline and 8 weeks ]
    Rate of fall of glucose in the blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females (postmenopausal, surgically sterile or using double-barrier method of contraception), aged 18-75 years, FPG 100-115 mg/dl at screening (average of 2 measurements during screening; no individual measurement outside of the range 92-125 mg/dl)
  • In good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis
  • HbA1c <6.5% at screening
  • Body mass index (BMI) in the range of 22-40 kg/m2 inclusive and with a stable (+/-2.5 kg) weight for the last 6 months
  • Subjects must be willing to:

    • Maintain prior exercise and dietary habits throughout the study
    • Comply with all study requirements
    • Provide written informed consent

Exclusion Criteria:

  • Pregnant or lactating females
  • Patients diagnosed with type 2 diabetes or that have taken glucose-lowering agents or insulin, except during pregnancy
  • Chronic oral or parenteral corticosteroid treatment (>7 consecutive days of treatment) within 8 weeks prior to screening
  • HIV protease inhibitors
  • Warfarin or phenytoin use
  • Triglycerides >500 mg/dl
  • History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection
  • History of dysphagia, swallowing disorders or intestinal motility disorder
  • History of pancreatitis
  • Uncontrolled hypothyroidism
  • Individuals with clinical hepatic disease or liver function tests greater than ≥2 times upper limits of normal within 30 days preceding the first dose of study drug
  • On a weight loss program with ongoing weight loss, or starting an intensive exercise program within 4 weeks of study initiation
  • Current or prior (within the past 3 months) treatment with a bile acid sequestrant (colesevelam, colestipol, colestimide, or cholestyramine)
  • Use of any investigational drug in the last 30 days
  • Donation of one unit (500 ml) or more of blood, significant blood loss equaling at least one unit of blood within the past 2 weeks or a blood transfusion within 8 weeks prior to screening
  • Employment by the research center

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00990184

Sponsors and Collaborators
Seattle Institute for Biomedical and Clinical Research
VA Puget Sound Health Care System
Principal Investigator: Steven E Kahn, MB CHB VA Puget Sound Healthcare System

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Seattle Institute for Biomedical and Clinical Research Identifier: NCT00990184     History of Changes
Other Study ID Numbers: 1.2
First Posted: October 6, 2009    Key Record Dates
Results First Posted: November 21, 2012
Last Update Posted: November 21, 2012
Last Verified: October 2012

Keywords provided by Seattle Institute for Biomedical and Clinical Research:
Impaired Fasting Glucose

Additional relevant MeSH terms:
Prediabetic State
Glucose Intolerance
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Diabetes Mellitus
Endocrine System Diseases
Colesevelam Hydrochloride
Hypoglycemic Agents
Physiological Effects of Drugs
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents